【화학정보학】 New Cancer Drugs Approved by the FDA in 20 years

New Cancer Drugs Approved by the FDA in 20 yeas 

 

추천글 : 【화학정보학】 물질 라이브러리 

출처 : FDA, 2021년 5월 기준

---

a. 약물 라이브러리

b. 약물 클래스 라이브러리

---

 

1. small molecule : name; generic name; target; class; indication; FDA approval time 순으로 정리

○ Tabrecta; Capmetinib (2); MET; Signaling/Kinase; NSCLC; 2020

○ Ayvakit; Avapritinib (2); PDGFRa; Signaling/Kinase; GIST; 2020

○ Retevmo; Selpercatinib (2); RET; Signaling/Kinase; NSCLC, Thyroid Cancer; 2020

○ Turalio; Pexidartnib; CSF1R, KIT, FLT3; Signaling/Kinase; Symptomatic Tenosynovial Giant Cell Tumor; 2019

○ Balversa; Erdafitinib (3); FGFR2/3; Signaling/Kinase; Bladder Cancer; 2019

○ Vitrakvl; Larotrectinib (2); TRK; Signaling/Kinase; Solid Tumors w/ NTRK Gene Fusion; 2018

○ Rydapt; Midostaurin (2); FLT3; Signaling/Kinase; AML; 2017

○ Xalkorl; Crizotinib (2); ROS1; Signaling/Kinase; NSCLC; 2016

○ Ibrance; Palbocicllib (3); CDK4/6; Signaling/Kinase; HR+/HER2- Breast Cancer; 2015

○ Zydellg, Piqray; Alpellsib, Idelalisib (5); PI3Ka, PI3Kd; Signaling/Kinase; HR+ HER2- Breast Cancer, CLL, Blood Cancer; 2014, 2019

○ Imbruvica; Ibrutinib (3); BTK; Signaling/Kinase; Mantle Cell Lymphoma, CLL; 2013

○ Mekinist; Trametinib (3); MEK; Signaling/Kinase; Melanoma; 2013

○ Xalkori; Crizotinib (5); ALK; Signaling/Kinase; NSCLC; 2011

○ Zelboraf; Vemurafenib (3); BRAF; Signaling/Kinase; Melanoma; 2011

○ Tykerb; Lapatinib (3); Her2; Signaling/Kinase; Breast; 2007

○ Sutent; Sunitinib (9); VEGFR; Signaling/Kinase; Solid Cancers; 2006

○ Iressa; Gefitinib (6); EGFR; Signaling/Kinase; NSCLC, Breast; 2003

○ Gleevec; Imatinib (6): ABL; Signaling/Kinase; CML, ALL; 2001

○ Lumakras; Sotorasib; KRAS; Signaling; NSCLC; 2021

○ Rapamune; Sirolimus, Rapamycin (3); mTOR; Signaling; RCC; 1999

○ Venclecta; Venetoclax; BCL2; Apoptosis; CLL, AML; 2016

○ Orgovyx; Relugolix; GnRH Receptor; GPCR; Prostate Cancer; 2020

○ Lutathera; Lutetium Lu177 dotatate; Somatostatin Receptor; GPCR; GEP-NETs; 2018

○ Erivedge; Vismodegib (2); SMO (Hedgehog pathway); GPCR; Basal Cell Carcinoma; 2012

○ Eulexin; Flutamide, Non-steroidal (6); Androgen Receptor; Nuclear Receptor; Prostate Cancer; 1989

○ Xpovlo; Selinexor; XPO1; Nuclear Export; MM; 2019

○ Lynparza; Olaparib (4); PARP Inh; DNA Repair; Ovarian Breast, Prostate, Pancreatic; 2014

○ Zolinza; Volinostat (4); HDAC; Epigenetics; Cutaneous T-cell Lymphoma; 2006

○ Tazverik; Tazemotostat; EZH2; Epigenetics; Epitheliod Sarcoma, Follicular Lymphoma; 2020

○ Tibsovo; Ivosldenib; IDH1; Epigenetic/Metabolism; AML; 2018

○ Idhifa; Enasidenib; IDH2; Epigenetic/Matabolism; AML; 2017

 

 

2. mAb(monoclonal antibody) : name; generic name; target; class; indication; FDA approval time 순으로 정리

○ Lartruvo; Olaratumab; PDGFRα; Signaling; Soft Tissue Sarcoma; 2016

○ Cyramza; Ramucirumab; VEGFR2; Signaling; Gastric Cancer; 2014

○ Avastin; Bevacizumab; VEGF-A; Signaling; Colorectal Cancer; 2004

○ Erbitux; Cetuximab (3); EGFR; Signaling; Colorectal Cancer, NSCLC; 2004

○ Herceptin; Trastuzumab (3); HER2; Signaling; Breast Cancer, Gastric, GEJ Cancer; 1998

○ Unituxin; Dinutuximab (2); GD2; ADCC/CDC; Neuroblastoma; 2015

○ Monjuvi; Tafasitamab; CD19; Immune; DLBCL; 2020

○ Empliciti; Elotuzumab; SLAMF7; Immune; MM; 2015

○ Darzalex; Daratumumab (2); CD38; Immune; MM; 2015

○ Tecentriq; Atezolizumab (3); PD-L1; Immune; Various Cancers; 2016

○ Keytruda; Pembrolizumab (4); PD-1; Immune; Various Cancers; 2014

○ Yervoy; Ipilimumab; CTLA-4; Immune; Various Cancers; 2011

○ Lemtrada; Alemtuzumab; CD52; Immune; CML; 2001

○ Rituxan; Rituximab (4); CD20; Immune; NHL, CLL; 1997 

 

 

3. bi-specific Ab : name; generic name; target; class; indication; FDA approval time 순으로 정리

○ Blincyto; Blinatumomab; CD3/CD19; Bi-specific Ab; ALL; 2014

○ Rybrevant; Amivantamab; EGFR/cMET; Bi-specific Ab; NSCLC; 2021

○ Not determined; Tebotelimab; PD-1/Lag3; Bi-specific Ab; Gastric, GEJ; P3

○ Not determined; Glofitamab (RG6026); CD3/CD20; Bi-specific Ab; DLBCL; P3

○ Not determined; Mosunetuzumab (RG7828); CD3/CD20; Bi-specific Ab; FL; P3 (BTD)

 

 

4. ADC : name; generic name; target; class; indication; FDA approval time 순으로 정리

○ Zynlonta; Loncastuximab-tesirine; CD19; ADC; DLBCL; 2021

○ Trodelvy; Sacituzumab-govitecan; Trop-2; ADC; TNBC; 2020

○ Blenrep; Belantamab-mefodotinf; BMCA; ADC; MM; 2020

○ Padcev; Enfortumab-vedotin; Nectin-4; ADC; Bladder cancer; 2019

○ Polivy; Polatuzumab-vedotin; CD76β; ADC; DLBCL; 2019

○ Besponsa; Inotuzumab-ozogamicin (2); CD22; ADC; ALL, Hairy Cell Leukemia; 2017

○ Kadcyla; Trastuzumab-emtansine (2); HER2; ADC; Breast Cancer; 2012

○ Adcetris; Brentuximab-vedotin; CD30; ADC; Hodgkin Lympoma, Systemic Anaplastic, Large Cell Lymphoma; 2011

○ Mylotarg; Gemtuzumab-ozogamicin; CD33; ADC; AML; 2000, 2017

 

 

5. CAR-T : name; generic name; target; class; indication; FDA approval time 순으로 정리

○ Abecma; Idecabtagene vicleucel; BCMA; CAR-T; MM; 2021

○ Kymriah; Tisagenlecleucel-T (4); CD19; CAR-T; DLBCL, FL, ALL, MCL; 2017 

 

입력: 2022.01.08 19:12